Skip Navigation


Human Molecular Genetics Advance Access originally published online on April 6, 2005
Human Molecular Genetics 2005 14(10):1341-1349; doi:10.1093/hmg/ddi144
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
14/10/1341    most recent
ddi144v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Finnis, M.
Right arrow Articles by Richards, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finnis, M.
Right arrow Articles by Richards, R. I.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Common chromosomal fragile site FRA16D mutation in cancer cells

Merran Finnis1,2, Sonia Dayan1,2, Lynne Hobson1,2, Georgia Chenevix-Trench3, Kathryn Friend2, Karin Ried2, Deon Venter4, Erica Woollatt2, Elizabeth Baker5,6 and Robert I. Richards1,2,*

1ARC Special Research Centre for the Molecular Genetics of Development, ARC-NHMRC Research Network in Genes and Environment in Development, School of Molecular and Biomedical Sciences, The University of Adelaide, Adelaide 5005, South Australia, 2Centre for Medical Genetics, Women's and Children's Hospital, North Adelaide 5006, South Australia, 3Queensland Institute for Medical Research, PO Royal Brisbane Hospital, Queensland 4029, Australia, 4Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria 3050, Australia, 5Department of Paediatrics, The University of Adelaide, Adelaide 5005, South Australia and 6Department of Cytogenetics, King Edward Memorial Hospital, Subiaco, WA, Australia

* To whom correspondence should be addressed. Tel: +618 83037541; Fax: +618 83034362; Email: robert.richards{at}adelaide.edu.au

Received February 4, 2005; Accepted March 30, 2005

Neither the molecular basis for common fragile site DNA instability nor the contribution of this form of chromosomal instability to cancer is clearly understood. Fragile site FRA16D (16q23.2) is within regions of frequent loss-of-heterozygosity (LOH) in breast and prostate cancers, is associated with homozygous deletions in various adenocarcinomas and t(14;16) chromosomal translocations in multiple myeloma. The FOR (WWOX) gene spans FRA16D and encodes a partner of p53 that also has a role in apoptosis. Previously untested 53 cancer cell lines were screened for deletions within the FOR/WWOX gene. Deletions were detected in Co115, KM12C and KM12SM. Homozygous deletions in these and two previously identified tumour cell lines were intragenic on both alleles, indicating a distinct mutation mechanism from that causing LOH. Identical FRA16D deletions in two cell lines (one derived from the primary carcinoma and the other from a secondary metastasis) demonstrate that FRA16D DNA instability can be an early, transient event. Sequence analysis across one deletion locates one endpoint within a polymorphic AT-dinucleotide repeat and the other adjacent to an AT-rich mini-satellite repeat implicating AT-rich repeats in FRA16D DNA instability. Another deletion is associated with de novo repetition of the 9 bp AT-rich sequence at one of the deletion endpoints. FRA16D deleted cells retain cytogenetic fragile site expression indicating that the deletions are susceptible sites for breakage rather than regions that confer fragility. Most cell lines with FRA16D homozygous deletions also have FRA3B deletions, therefore common fragile sites represent highly susceptible genome-wide targets for a distinct form of mutation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Microbiol. Mol. Biol. Rev.Home page
G.-F. Richard, A. Kerrest, and B. Dujon
Comparative Genomics and Molecular Dynamics of DNA Repeats in Eukaryotes
Microbiol. Mol. Biol. Rev., December 1, 2008; 72(4): 686 - 727.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Varshavsky
From the Cover: Targeting the absence: Homozygous DNA deletions as immutable signposts for cancer therapy
PNAS, September 18, 2007; 104(38): 14935 - 14940.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Nymark, H. Wikman, S. Ruosaari, J. Hollmen, E. Vanhala, A. Karjalainen, S. Anttila, and S. Knuutila
Identification of Specific Gene Copy Number Changes in Asbestos-Related Lung Cancer
Cancer Res., June 1, 2006; 66(11): 5737 - 5743.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N.-S. Chang, J. Doherty, A. Ensign, L. Schultz, L.-J. Hsu, and Q. Hong
WOX1 Is Essential for Tumor Necrosis Factor-, UV Light-, Staurosporine-, and p53-mediated Cell Death, and Its Tyrosine 33-phosphorylated Form Binds and Stabilizes Serine 46-phosphorylated p53
J. Biol. Chem., December 30, 2005; 280(52): 43100 - 43108.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
T. W. Glover, M. F. Arlt, A. M. Casper, and S. G. Durkin
Mechanisms of common fragile site instability
Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R197 - R205.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F.-J. Lai, C.-L. Cheng, S.-T. Chen, C.-H. Wu, L.-J. Hsu, J. Y.-Y. Lee, S.-C. Chao, M.-C. Sheen, C.-L. Shen, N.-S. Chang, et al.
WOX1 Is Essential for UVB Irradiation-Induced Apoptosis and Down-Regulated via Translational Blockade in UVB-Induced Cutaneous Squamous Cell Carcinoma In vivo
Clin. Cancer Res., August 15, 2005; 11(16): 5769 - 5777.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.